Antibody Platforms
Antibody discovery platforms with advanced fully humanized mouse models
License the leading in vivo discovery platform for fully human monoclonal and bispecific antibodies
Access our foundational suite of highly immunocompetent transgenic mice, engineered to drive the greatest potential sequence and epitopic diversity of unique human antibodies for your target. Resulting antibodies exhibit high affinity and excellent developability profiles, requiring little-to-no optimization.
Accessible terms
Flexible access with expert support for drug discovery teams of all sizes to achieve the best results.
Continuous innovation
Access an-ever expanding portfolio of transgenic strains plus bespoke strains custom-tailored to your project.
Rich discovery output
The platform delivers wide epitopic coverage and diverse binding affinities, supported by heathy cellularity, a human-like repertoire, and a robust immune response even against challenging targets.
Proven track record
Trusted by over 170+ partners, we have a demonstrated history of success with 10 antibodies in clinical development and more then 60+ partnered programs.
Tackle your most challenging monoclonal and bispecific programs with uniquely tailored strains
ATX-Gx™
Under a standard ATX-Gx license, partners have access to:
Under a standard ATX-Gx license, partners have access to:
ATX-GK Mouse
With human heavy and kappa light chain repertoires.
ATX-Gl Mouse
With human lambda light chain diversity.
ATX-Gkh Hyperimmune Mouse
Engineered to increase production of antigen specific B cells for challenging targets.
ATX-CLC
Available to partners through our Antibody Discovery Services offering.
Available to partners through our Antibody Discovery Services offering.
ATX-CLC
CLC platform generates human antibodies with a single light chain sequence enabling the production of highly modular and manufacturable bispecifics.
Maximize diversity with Alloy's suite of mice
Human heavy kappa light chain antibodies against a wide range of targets
The ATX-GK mouse was engineered with a diverse human heavy and kappa light chain repertoire containing 41 VH and 19 VK gene segments. The mice are highly immunocompetent with normal B cell development and produce antibodies with V-gene usage and CDRH3 lengths consistent with normal human sequences.
ATX-GK mice deliver broad epitopic coverage, high affinity, and great species cross-reactivity even against challenging targets such as GPCRs using a range of immunization antigens including proteins, mRNA, DNA, and cells. For further diversity, the ATX-GK strain is available on a C57BL/6, BALB/c, or cross background with increased immune response.
Human lambda light chain antibodies for sequence diversity against challenging targets
Lambda antibodies comprise 10% of all clinical antibody programs and provide an orthogonal set of diversity to the ATX-GK kappa repertoire for greater epitopic coverage.
The ATX-GL strain was engineered with 31 VL gene segments to produce a diverse repertoire of human lambda light chain antibodies. ATX-GL mice are highly immunocompetent and produce high affinity and developable lambda antibodies against a wide range of therapeutic targets.
ATX-GKH hyperimmune strain engineered for increased antigen specific B cell production
ATX-GKH mice contain the full human heavy and kappa light chain repertoire of Alloy’s ATX-GK animals, but are further engineered with three genetic modifications to enhance the immune response.
ATX-GKH have significantly enlarged lymphoid organs, increased titers, faster IgM to IgG class-switching, expanded populations of antigen specific B cells, and produce 5-10 fold higher numbers of antigen specific B cells, simplifying recovery and enabling multiple downstream workflows for enrichment or sequencing especially against high homology and multipass transmembrane targets.
Common light chain strains for highly modular and manufacturable bispecific development
Alloy’s common light chain (ATX-CLC) mice, available exclusively through our Antibody Discovery Services, solve the traditional bispecific challenge of heavy chain and light chain (HC/LC) pairing by producing a diverse repertoire of antibody heavy chains paired with a single light chain sequence.
Monoclonal antibodies discovered with the ATX-CLC mice can be readily mixed and matched in a range of bispecific formats while maintaining their native fragment antigen binding (Fab) architecture leading to highly manufacturable bispecifics that maintain the binding affinity of the parental monoclonals. Alloy offers four ATX-CLC strains, each containing a single light chain sequence (VK1, VK3, VK4, and VL1) selected for manufacturability, use in clinical or approved antibody drugs, pairing with diverse VH sequences, and structural diversity across strains.
Access to MabForge Service
Your antibody sequences to characterization in just 3 weeks
As an ATX-Gx licensee, accelerate your hits through exclusive access to our high-throughput screening mAbForge™ workflow as an additional service.
Empower your antibody discovery with ATX-Gx
Antibody news & resources
